A feasibility study of bevacizumab plus dose-dense doxorubicin-cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel in early-stage breast cancer.

Clin Cancer Res 2011 May 24;17(10):3398-407. Epub 2011 Feb 24.

Breast Cancer Medicine Service, Memorial Sloan-Kettering Cancer Center, Weill Cornell Medical College, New York, New York 10065, USA.

Purpose: Bevacizumab confers benefits in metastatic breast cancer but may be more effective as adjuvant therapy. We evaluated the cardiac safety of bevacizumab plus dose-dense doxorubicin-cyclophosphamide (ddAC) → nanoparticle albumin-bound (nab)-paclitaxel in human epidermal growth factor receptor 2 normal early-stage breast cancer.

Experimental Design: Eighty patients with normal left ventricular ejection fraction (LVEF) were enrolled. Bevacizumab was administered for 1 year, concurrently with ddAC → nab-paclitaxel then as a single agent. LVEF was evaluated at months 0, 2, 6, 9, and 18. This regimen was considered safe if fewer than three cardiac events or fewer than two deaths from left ventricular dysfunction occurred. Correlative studies of cardiac troponin (cTn) and plasma renin activity (PRA) were conducted.

Results: The median age was 48 years (range, 27-75 years), and baseline LVEF was 68% (53%-82%). After 39 months' median follow-up (5-45 months): median LVEF was 68% (53%-80%) at 2 months (n = 78), 64% (51%-77%) at 6 months (n = 66), 63% (48%-77%) at 9 months (n = 61), and 66% (42%-76%) at 18 months (n = 54). One patient developed symptomatic LV dysfunction at month 15. Common toxicities necessitating treatment discontinuation were hypertension (HTN, 4%), wound-healing complications (4%), and asymptomatic LVEF declines (4%). Neither cTn nor PRA predicted congestive heart failure (CHF) or HTN, respectively.

Conclusions: Bevacizumab with ddAC → nab-paclitaxel had a low rate of cardiac events; cTn and PRA levels are not predictive of CHF or HTN, respectively. The efficacy of bevacizumab as adjuvant treatment will be established in several ongoing phase III trials.

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-10-1969DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4994894PMC
May 2011
46 Reads

Publication Analysis

Top Keywords

ddac →
12
→ nab-paclitaxel
8
early-stage breast
8
breast cancer
8
left ventricular
8
lvef 68%
8
nanoparticle albumin-bound
8
ctn pra
8
chf htn
8
dose-dense doxorubicin-cyclophosphamide
8
cardiac events
8
bevacizumab dose-dense
8
months
6
bevacizumab
6
lvef
5
months' median
4
median follow-up
4
follow-up 5-45
4
5-45 months
4
53%-82% months'
4

Altmetric Statistics

Similar Publications